Evoque TTVR system linked to favorable outcomes in new real-world analysis
The Evoque transcatheter tricuspid valve replacement (TTVR) system from Edwards Lifesciences is associated with positive real-world outcomes after 30 days, according to new data presented at TCT 2025 in San Francisco.
Cardiologist Rahul P. Sharma, MBBS, director of structural interventions at Stanford Healthcare and associate director of the cath lab at Stanford University, shared the findings with a large crowd during a late-breaking clinical trial session. Sharma’s presentation focused on data from more than 1,000 patients treated with the Evoque device from February 2024 to March 2025. The mean patient age was 77.1 years old, and 69.1% of patients were women. All data came from the STS/ACC TVT Registry.
Overall, Sharma and his team found that the real-world performance outdid what clinicians witnessed during clinical trials. The rates of all-cause mortality, cardiovascular mortality, stroke and major or life-threatening bleeding events after 30 days were 3.1%, 2%, 0.2% and 1.3%, respectively. New pacemakers were required for 14.9% of patients, and 3.1% of patients required a hospitalization due to heart failure symptoms in those first 30 days.
The median procedure time was 103 minutes, median length of stay was two days and 93.8% of patients were discharged to home instead of a nursing or rehabilitation facility. In addition, the mean Kansas City Cardiomyopathy Questionnaire Overall Summary Score was 69.5, much higher than the 47.1 calculated prior to treatment.
“We now have established a comprehensive portfolio of mitral and tricuspid repair and replacement technologies to ensure patients can receive the right therapy to meet their unique needs,” Daveen Chopra, the corporate vice president of transcatheter mitral and tricuspid therapies at Edwards Lifesciences, said in a statement. “The depth and breadth of evidence across our therapies reinforces the compounding value our innovations continue to deliver for patients, physicians and the healthcare system.”
The Evoque system received CE mark approval in 2023. In 2024, it was the first TTVR device to gain full U.S. Food and Drug Administration approval.
Click here for more real-world data related to the Evoque TTVR system. Click here to read about a recent heart transplant recipient who underwent treatment with the device.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.